Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics

Drugs and Aging

Volumn 21, Issue 13, 2004, Pages 825-832

  Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CISPLATIN; CORTICOSTEROID; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOTOXIC AGENT; DEXAMETHASONE; DOLASETRON MESILATE; GEMCITABINE; GRANISETRON; HYDRODOLASETRON; METOCLOPRAMIDE; NAVELBINE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PALONOSETRON; SEROTONIN 3 ANTAGONIST; TROPISETRON;

BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DRUG TOLERABILITY; ELDERLY CARE; GASTROINTESTINAL DISEASE; HEPATOBILIARY DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; MALNUTRITION; MENTAL DISEASE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; OSTEOARTHROPATHY; POLYPHARMACY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW;

AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; FEMALE; GERIATRICS; HUMANS; INCIDENCE; LUNG NEOPLASMS; NEOPLASMS; POLYPHARMACY; POSTOPERATIVE NAUSEA AND VOMITING; RECEPTORS, SEROTONIN, 5-HT3;

EID: 8444239709     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421130-00001     Document Type: Review

References (56)

1. Yancik R, Ries LA. Aging and cancer in America. Hematol/Oncol Clin North Am 2000; 14: 17-23
2. World Health Organization. WHO cancer mortality database [online]. Available from URL: http://www.depdb.iarc.fr/who/menu.htm [Accessed 2004 Jan 1]
3. US Census Bureau. IDB population pyramids [online]. Available from URL: http://www.census.gov./ipc/www/idbpyr.html [Accessed 2004 Jan 1]
4. Kris ML, Cubeddu LX, Gralla RJ, et al. Are more antiemetic trials with a placebo necessary? Cancer 1996; 78: 2193-8
5. Di Maio M, Perrone F, Gallo C, et al. Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer 2003; 89: 1013-21
6. Lindley CM, Hirsch JD, O'Neill CV, et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992; 1: 331-40
7. O'Brien BJ, Rusthoven J, Rocchi A, et al. Impact of chemotherapy- associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. Can Med Assoc 1993; 149: 296-302
8. Laszlo J. Emesis as limiting toxicity in cancer chemotherapy. In: Laszlo J, editor. Antiemetics and cancer chemotherapy. London: Williams and Wilkins, 1983: 1-5
9. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33 (4): 278-85
10. Durnas C, Loi CM, Cusack BJ. Hepatic drug metabolism and aging. Clin Pharmacokinet 1990; 19 (5): 359-89
11. Hanninen T, Koivisto K, Reinikainen KJ, et al. Prevalence of ageing-associated cognitive decline in an elderly population. Age Ageing 1996; 25 (3): 201-5
12. Kyle UG, Unger P, Mensi N, et al. Nutrition status in patients younger and older than 60 y at hospital admission: a controlled population study in 995 subjects. Nutrition 2002; 18 (6): 463-9
13. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomised trial. J Natl Cancer Inst 2003; 95: 362-72
14. Fried LP, Bandeen-Roche K, Kasper JD, et al. Association of comorbidity with disability in older women: the women's health and aging study. J Clin Epidemiol 1999; 52: 27-37
15. Jorgensen T, Johansson S, Kennerfalk A, et al. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 2001; 35: 1004-9
16. Hanlon JT, Fillenbaum GG, Ruby CM, et al. Epidemiology of over-the-counter drug use in community dwelling elderly. Unites States perspective. Drugs Aging 2001; 18: 123-31
17. Karas Jr S. The potential for drug interactions. Ann Emerg Med 1981; 10: 627-30
18. May FE, Stewart RB, Cluff LE. Drug interactions and multiple drug administration. Clin Pharmacol Ther 1977; 22: 322-9
19. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-7
20. Monfardini S, Sorio R, Boes GH, et al. Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug development studies. Cancer 1995; 76: 333-8
21. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999; 17 (9): 2971-94
22. Koeller JM, Aapro MS, Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 2002; 10: 519-22
23. MASSC. Perugia International Cancer Conference VII. Consensus conference on antiemetic therapy. Perugia, March 29-31, 2004 [online]. Available from URL: http://www.mascc.org/files/MASCC_guide-slides060804-1st_ed.pps [Accessed 2004 Aug 1]
24. Van Wijngaarden I, Tulp MT, Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 1990; 138: 301-12
25. 3 receptors, in vitro. Br J Pharmacol 1995; 114: 851-9
26. Anzemet® (dolasetron mesylate) [prescribing information]. Kansas City (MO): Aventis Pharmacuetical Inc., 2003 Oct
27. 3 antagonist. Eur J Cancer 1990; 26 Suppl. 1: S12-S5
28. Sweetland J, Lettis S, Fowler PA, et al. Duration of the inhibitory effect of intravenous ondansetron on intradermal 5-HT-induced flare [abstract]. Br J Clin Pharmacol 1992; 33: 565P
29. Addelman M, Erlichman C, Fine S, et al. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol 1990; 8: 337-41
30. Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 1995; 29: 95-109
31. Lippert CL, Dimmitt DC, Martin L, et al. Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose ciplatin-containing chemotherapy. Am J Ther 1999; 6: 129-35
32. Kees F, Farber L, Bucher M, et al. Pharmacokinetics of therapeutic doses of tropisetron in heatlhy volunteers. Br J Clin Pharmacol 2001; 52: 705-7
33. Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 2004; 15: 330-7
34. Newberry NR, Watkins CJ, Sprosen TS, et al. BRL 46470 potently antagonizes neural reponses activated by 5-HT3 receptors. Neuropharmacol 1993; 32: 729-35
35. Blower PR. 5-HT3 receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J 2002; 8: 405-14
36. AIoxi® (palonosetron HCl) injection [US prescribing information]. Bloomington (MN): MGI Pharma, Inc., 2003 Jul
37. Navoban® (tropisetron) [prescribing information]. North Ryde (NSW): Novartis Pharmaceutical Australia Pty Ltd, 1997
38. Benedict CR, Arbogast R, Martin L, et al. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 1996; 28: 53-9
39. Audhuy B, Cappelaere, Martin M, et al. A double-blind, randomised comparison of the anit-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Can 1996; 32A (5): 8070-13
40. Schnell FM, Coop AJ. An evaluation of potential signals for ventricular arrhythmia and cardiac arrest with dolasetron and granisetron in the FDA combined Spontaneous Reporting System/Adverse Event Reporting System (SRS/AERS) [abstract no. 371. 8th International Conference on Geriatric Oncology, Cancer in the Elderly; 2003 Nov 21-22; Rome
41. Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother 2003; 37: 1276-86
42. Carmichael J, Harris AL. High-dose i.v. granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerability. Anticancer Drugs 2003; 14: 739-44
43. Carmichael J, Harris AL. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy. Cancer Chemother Pharmacol 2004; 53: 123-8
44. Gilbert CJ, Petros WP, Vredenburgh J, et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Can Chemo Pharmacol 1998; 42: 497-503
45. Cagnoni PJ, Matthes S, Day TC, et al. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Marrow Trans 1999; 24: 14
46. Stanford BJ, Stanford SC. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? J Psychopharmacol 1999; 13: 313-7
47. De Witte JL, Schoenmaekers B, Sessler DI, et al. The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron. Anesth Analg 2001; 92 (5): 1319-21
48. Blum RA, Majumdar A, McCrea J, et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003; 25: 1407-19
49. Youlten L. The effect of repeat dosing with cimetidine on the pharmacokinetics of intravenous granisetron in healthy volunteers. J Pharm Pharmacol 2004; 56: 169-75
50. Watanabe Y, Nakajima H, Nozaki K, et al. The effect of granisetron on in vitro metabolism of paclitaxel and docetaxel. Cancer J 2003; 9: 67-70
51. Gridelli C, Maione P, Rossi A. Corticosteroids underemployment in delayed chemotherapy-induced nausea and emesis with poor adherence to American Society of Clinical Oncology Guidelines: is this a reasonable clinical choice for the elderly? J Clin Oncol 2003; 21: 4066-9
52. Dexamethaonse [prescribing information]. Cambridge: Organon Laboratories Ltd, 2002 Sep
53. Campos D, Pereia JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001; 19: 1759-67
54. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003; 97: 2290-300
55. Bauwens G, Aapro MS, Pendergrass K, et al. The oral NK1 receptor antagonist aprepitant is effective for the prevention of chemotherapy induced nausea and vomiting in elderly patients receiving high-dose cisplatin [abstract no. 3159]. Proc Am Soc Clin Oncol 2003; 22: 786
56. Emend® (aprepitant) capsules [US prescribing information]. Whitehouse Station (NJ): Merck & Co, Inc., 2003 May